FibroBiologics, Inc. Common Stock (FBLG )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol FBLG
- Company FibroBiologics, Inc. Common Stock
- Price $0.31
- Changes Percentage -8.14
- Change -0.0277
- Day Low $0.31
- Day High $0.39
- Year High $1.53
- Year Low $0.22
- Market Cap $16,604,287
- Price Avg 50 EMA (D) $0.31
- Price Avg 200 EMA (D) $0.48
- Exchange NASDAQ
- Volume 843,733
- Average Volume 1,890,583
- Open $0.34
- Previous Close $0.34
- EPS -0.42
- PE -0.94
- Earnings Announcement 2026-05-13 04:00:00
- Shares Outstanding $41,919,431
Company brief: FIBROBIOLOGICS, INC. COMMON STOCK (FBLG )
- Healthcare
- Biotechnology
- Mr. Peter O'Heeron
- https://www.fibrobiologics.com
- US
- N/A
- 02-01-2024
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Corporation News
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
globenewswire.com -- HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...